IM 1240
Alternative Names: IM-1240Latest Information Update: 05 Jun 2024
At a glance
- Originator Purple Biotech
- Class Antineoplastics; Immunotherapies; Trispecific antibodies
- Mechanism of Action Natural killer cell stimulants; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 05 Jun 2024 Purple Biotech announces intention to IND application to US FDA for Solid tumours in 2025
- 21 Feb 2023 Preclinical trials in Solid tumours in Israel (Parenteral), before February 2023 (Purple Biotech pipeline, February 2023)
- 31 Dec 2022 Purple Biotech has patents pending for IM 1240 in Australia, Brazil, Canada, China, Europe, Israel, India, Japan, the Republic of Korea, Mexico, USA